Ann: Preclinical Data Support Developmnt AMP945 Pancreatic Cancer, page-3

• AMP945 enhances activity of the chemotherapy in models of pancreatic cancer
• Results support progression of AMP945 into Phase 2 clinical trial
Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”, a
company developing new approaches for the treatment for cancer and fibrosis, is pleased to announce
further data that it has received during its collaboration with Professor Paul Timpson of the Garvan
Institute of Medical Research, Sydney (“Garvan”.
In March, Amplia announced that it had agreed terms for a collaboration with the Garvan. This
collaboration has brought together Amplia’s clinical-stage FAK inhibitors with the Garvan’s unique
insights into FAK biology and its clinical research network.
Amplia has now received data from work conducted under this collaboration in which AMP945 was
tested in a range of different in vitro and in vivo experimental systems that have been established over
many years in Professor Paul Timpson’s laboratory at the Garvan. These data have demonstrated that
AMP945 impacts several key markers of disease, including the level of fibrosis and collagen maturity
in the tumour environment in a mouse model of pancreatic cancer. Furthermore, when combined with
gemcitabine/Abraxane®, which is a standard of care in pancreatic cancer, AMP945 enhances the
activity of the chemotherapy as determined by key indicators of cell death and of cancer cell
proliferation. Specifically, after a single round of treatment, AMP945, in combination with
gemcitabine/Abraxane®, caused a significant increase in levels of cleaved Caspase-3 which is a marker
of cancer cell death. In addition, Ki67, a marker of cancer cell proliferation, was significantly decreased
after dosing with both AMP945 and gemcitabine/Abraxane